EUVIMEDOpdag EUVIMED
Open access

IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia

Alexandra E Kovach iD, Maximilian Wengyn, My H Vu iD, Andrew Doan iD, Gordana Raca, Deepa Bhojwani

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30996 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2024. Written by Alexandra E Kovach and 5 co-authors. Institution: Hematopathology, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA. Major MEDLINE topics: Hispanic or Latino, Ikaros Transcription Factor, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Cited 4 times so far (Crossref); 44 references. The full text is freely available in PubMed Central. Funded by: Concern Foundation for Cancer Research, and Tri Delta, National Cancer Institute R25, Children's Hospital Los Angeles.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Compared to other ethnicities, Hispanics/Latinos (H/L) have a high incidence of acute lymphoblastic leukemia (ALL), enrichment of unfavorable ALL genetic subtypes, and worse outcomes, even after correcting for socioeconomic factors. We previously demonstrated increased incidence of the high‐risk genetic drivers IKZF1 deletion and IGH::CRLF2 rearrangement in H/L compared to non‐H/L children with B‐ALL. Here in an expanded pediatric cohort, we sought to identify novel genetic drivers and secondary genetic alterations in B‐ALL associated with H/L ethnicity. Procedure Comprehensive clinicopathologic data from patients with B‐ALL treated from 2016 to 2020 were analyzed. Subtype was determined from karyotype, fluorescence in situ hybridization (FISH), chromosome microarray (CMA), and our next‐generation sequencing (NGS) panel (OncoKids). Non‐driver genetic variants were also examined. p ‐Values less than .05 (Fisher's exact test) were considered significant.

Results

Among patients with B‐ALL at diagnosis ( n = 273), H/L patients (189, 69.2%) were older ( p = .018), more likely to present with CNS2 or CNS3 disease ( p = .004), and NCI high‐risk ALL ( p = .014) compared to non‐H/L patients. Higher incidence of IGH::CRLF2 rearrangement (B‐ALL, BCR::ABL1‐like, unfavorable; p = .016) and lower incidence of ETV6::RUNX1 rearrangement (favorable, p = .02) were also associated with H/L ethnicity. Among secondary (non‐subtype‐defining) genetic variants, B‐ALL in H/L was associated with IKFZ1 deletion alone ( p = .001) or with IGH::CRLF2 rearrangement ( p = .003). The IKZF1 PLUS profile ( IKZF1 deletion plus CDKN2A/2B del, PAX5 del, or P2RY8::CRLF2 rearrangement without DUX4 rearrangement) was identified as a novel high‐risk feature enriched in H/L patients ( p = .001).

Conclusions

Our study shows enrichment of high‐risk genetic variants in H/L B‐ALL and raises consideration for novel therapeutic targets.

Subjects

MeSH terms (MEDLINE)

Hispanic or LatinoIkaros Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleBiomarkers, TumorFollow-Up StudiesPrognosisSurvival Rate

Author keywords

B‐ALLHispanicacute lymphoblastic leukemiaethnicityleukemiapediatric

Substances

Biomarkers, TumorIkaros Transcription FactorIKZF1 protein, human

Authors and institutions

  • Hematopathology, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
  • Miller School of Medicine of University of Miami, Miami, Florida, USA.
  • Biostatistics Core, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Cytogenomics, Center for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.

ORCID profiles: Alexandra E Kovach, My H Vu, Andrew Doan

Funding

  • Concern Foundation for Cancer Research, and Tri Delta
  • National Cancer Institute R25
  • Children's Hospital Los Angeles
  • NCI NIH HHS
  • Norris Comprehensive Cancer Center in Los Angeles
  • Interdisciplinary Research
  • Children's Hospital Los Angeles (CH/LA) Department of Pathology and Laboratory Medicine (PLM) Translational Research Fund

Cite

APA

Kovach, A. E., Wengyn, M., Vu, M. H., Doan, A., Raca, G., & Bhojwani, D. (2024). IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30996

Vancouver

Kovach AE, Wengyn M, Vu MH, Doan A, Raca G, Bhojwani D. IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30996

BibTeX
@article{Kovach2024,
  author = {Kovach, Alexandra E and Wengyn, Maximilian and Vu, My H and Doan, Andrew and Raca, Gordana and Bhojwani, Deepa},
  title = {IKZF1 PLUS alterations contribute to outcome disparities in Hispanic/Latino children with B‐lymphoblastic leukemia},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30996}
}
Start for free →